Markets Stocks Economy Crypto Earnings Banking Energy
Home Markets Feature
Markets · Exclusive

European ADRs Rally as Bank Stocks Lead Broad Advance in US Trading

European ADRs Rally as Bank Stocks Lead Broad Advance in US Trading
Markets · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Jul 30, 2026 3 min read

European companies' US-listed shares jumped in Thursday morning trading, pushing the S&P Europe Select ADR Index up 1.84% to 1,938.04 as of 11:15 AM EDT. The move was led by a broad rally in bank American depositary receipts (ADRs), with several major financial names posting gains of 4% or more.

ADRs are shares of foreign companies that trade on US stock exchanges, allowing American investors to buy and sell international stocks in US dollars without dealing with foreign exchanges or currency conversion. The S&P Europe Select ADR Index tracks the performance of a basket of these instruments, giving a snapshot of how US-based investors are pricing European equities during the trading day.

Banks lead the charge

The strongest gains came from the banking sector. ING, the Dutch financial giant, surged 7.0%, while Spain's BBVA rose 6.8% and Santander gained 4.6%. UK lenders also saw strong demand, with Barclays up 5.6% and Lloyds Banking Group climbing 5.4%. This kind of coordinated, same-direction move in bank ADRs often signals a shift in investor sentiment toward European financials, potentially reflecting optimism about interest rate margins, economic growth, or regulatory developments.

The rally comes amid a backdrop where European banks have been reporting solid earnings. Recent results from Deutsche Bank and UBS beat Q2 forecasts, though European banks still trade at a discount to their US rivals. That valuation gap may be attracting bargain hunters, especially if investors believe the European economy is stabilizing.

Nokia gains, Sanofi and Endava lag

Not all European ADRs moved higher. Nokia, the Finnish telecom equipment maker, was among the biggest gainers, though the brief did not specify the exact percentage move. On the downside, French pharmaceutical company Sanofi and UK-based IT services firm Endava both fell, dragging on the index. The divergence highlights that while the overall market was strong, sector-specific factors still drove individual stock performance.

Sanofi's decline may reflect ongoing concerns about drug pricing pressures or pipeline setbacks, while Endava, which provides digital transformation services, could be facing headwinds from a slowdown in corporate IT spending. The broader European tech sector has been under pressure this year, as rising interest rates make growth stocks less attractive.

What this means for investors

For everyday investors, the rally in European ADRs is a reminder that international diversification can offer opportunities beyond US markets. When European banks rally, it often signals confidence in the region's economic outlook, which can benefit a range of sectors. However, the mixed performance—with some stocks falling—underscores the importance of looking at individual companies rather than assuming all European stocks move together.

Investors who hold ADRs directly or through international ETFs should watch for continued strength in financials, as bank stocks are often sensitive to interest rate changes and economic data. The Bank of England recently held rates steady, which may have provided some support for UK lenders. Meanwhile, the energy sector has been a key driver of European profit growth this quarter, though energy ADRs were not highlighted in today's move.

For those considering adding European exposure, it's worth noting that ADRs carry currency risk—fluctuations in the euro or pound against the dollar can affect returns. But for US-based investors, they offer a convenient way to invest in foreign companies without opening overseas brokerage accounts.

Looking ahead, market participants will be watching for further earnings reports from European banks and any signals from the European Central Bank on interest rate policy. If the rally in bank ADRs continues, it could be a sign that the long-standing discount on European financials is starting to narrow.

More from this story

Next article · Don't miss

Bristol-Myers strong quarter tempered by launch delays, RBC says

Bristol-Myers Squibb delivered a strong second quarter, but RBC Capital Markets warns that delays for two key drugs, milvexian and Cobenfy, could keep the stock range-bound. RBC lifted its full-year revenue forecast to $50 billion.

Read the story →
Bristol-Myers strong quarter tempered by launch delays, RBC says